Accuray Incorporated (ARAY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.84+0.31 (+5.61%)
At close: 4:00 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close5.53
Bid5.45 x 2000
Ask10.90 x 500
Day's Range5.51 - 5.85
52wk Range4.75 - 7.54
1y Target EstN/A
Market Cap476.4M
P/E Ratio (ttm)-18.25
Avg Vol (3m)613,520
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Accuray (ARAY) Grapples with Multiple Issues: Dump Now?
    Zacks16 hours ago

    Accuray (ARAY) Grapples with Multiple Issues: Dump Now?

    On Sep 23, we issued an updated research report on Sunnyvale, CA???based Accuray Inc. (ARAY), a leading developer and designer of radiosurgery and radiation therapy systems for the treatment of tumors.

  • PR Newswire19 hours ago

    Prospective, Multi-Institutional Study Shows Five Treatments with the CyberKnife® System Provide Excellent Disease Control for Prostate Cancer Patients

    SUNNYVALE, Calif., Sept. 27, 2016 /PRNewswire/ -- Accuray Incorporated (ARAY) announced today that data from a prospective, 21 center study showed 97 percent of low- and intermediate-risk prostate cancer patients had excellent cancer control five years after receiving stereotactic body radiation therapy (SBRT) administered with the CyberKnife® System. The study was presented during an oral session yesterday at the American Society for Radiation Oncology (ASTRO) 58th Annual Meeting and was one of 15 to be selected out of thousands of abstracts for presentation during an ASTRO press conference, scheduled for today. It offers a much shorter course of treatment for prostate cancer patients than conventional radiation and is noninvasive (no conventional surgery involved).

  • PR Newswire6 days ago

    Accuray to Unveil New Technology at the ASTRO 2016 Annual Meeting

    SUNNYVALE, Calif., Sept. 22, 2016 /PRNewswire/ -- New data on the Accuray (NASDAQ: ARAY) CyberKnife® and TomoTherapy® Systems will be shared by leading radiation oncology practitioners, and the Company's ...